Is Inovio Pharmaceuticals a Buy?
Inovio Pharmaceuticals (NASDAQ: INO) was already a highly promising small-cap biotech stock before the coronavirus pandemic began. Since then, however, the company has quickly become among the most exciting -- if not volatile -- vaccine developers on the market.
The company's COVID-19 vaccine candidate, INO-4800, was one of the first vaccines to begin human clinical trials, granting it a headstart over other pharmaceutical giants with candidates starting testing later this year. However, Inovio also has a number of other things going for it. Does its coronavirus work make Inovio an automatic buy for investors? Let's do dive into the research and find out.
Image source: Getty Images.
Source Fool.com
